Invention Grant
- Patent Title: Reprogramming bone endothelial cells for use in bone angiogenesis and osteogenesis
-
Application No.: US15029186Application Date: 2014-10-14
-
Publication No.: US10053668B2Publication Date: 2018-08-21
- Inventor: Ralf H. Adams , Anjali Kusumbe , Saravana Ramasamy
- Applicant: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.
- Applicant Address: DE Munich
- Assignee: Max-Planck-Gesellschaft zur Föderung der Wissenschaften e.V.
- Current Assignee: Max-Planck-Gesellschaft zur Föderung der Wissenschaften e.V.
- Current Assignee Address: DE Munich
- Agency: Knobbe, Martens, Olson & Bear, LLP
- Priority: EP13188509 20131014
- International Application: PCT/EP2014/072069 WO 20141014
- International Announcement: WO2015/055688 WO 20150423
- Main IPC: C07H21/02
- IPC: C07H21/02 ; C07H21/04 ; C12N5/077 ; C12N5/071 ; C12Q1/6881 ; G01N33/569
Abstract:
The present invention relates to a factor for reprogramming bone endothelial cells to promote bone angiogenesis and osteogenesis as well as to an ex vivo method for reprogramming a bone endothelial cell to achieve cells able to mediate bone angiogenesis and osteogenesis. The subtype of bone endothelial cells mediating bone angiogenesis and osteogenesis express CD31 and Endomucin as markers.
Public/Granted literature
- US20160257934A1 REPROGRAMMING BONE ENDOTHELIAL CELLS FOR USE IN BONE ANGIOGENESIS AND OSTEOGENESIS Public/Granted day:2016-09-08
Information query
